A Scoping Review of Precision Medicine in Breast Reconstruction (2011-2025).

IF 3 3区 医学 Q2 HEALTH CARE SCIENCES & SERVICES
Zain Aryanpour, Alec S McCranie, Jason W Yu, Julian Winocour, Katie G Egan, David Mathes, Christodoulos Kaoutzanis
{"title":"A Scoping Review of Precision Medicine in Breast Reconstruction (2011-2025).","authors":"Zain Aryanpour, Alec S McCranie, Jason W Yu, Julian Winocour, Katie G Egan, David Mathes, Christodoulos Kaoutzanis","doi":"10.3390/jpm15050178","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Personalization of medical care is a significant topic of interest. Precision medicine denotes customized medical treatments based on individual genetic, molecular, and/or biomarker data. We conducted a scoping review to identify studies exploring precision medicine in breast reconstruction. <b>Objectives:</b> (1) To map the existing literature, (2) to identify key concepts, and (3) to discuss current and future clinical implications of precision medicine in breast reconstruction. <b>Eligibility criteria:</b> Indexed journal articles (primary research studies) relating to precision medicine in breast reconstruction written in the English language. <b>Sources of evidence:</b> Medline (via Pubmed), Web of Science, and the Cochrane Library. <b>Charting methods:</b> Data charting of selected studies was performed independently by two reviewers using Microsoft Excel. Any discrepancies in data charting were addressed through inter-reviewer discussion and/or expert review. <b>Results:</b> Of 321 initial records, 9 studies that were published between 2011 and 2025 were included in the final review. Eight studies focused predominantly on genomics, and one study focused predominantly on targeted therapies. Genomic-based studies were frequently implemented to evaluate patient risk and inform clinical decision-making, while targeted therapies were used to optimize reconstructive outcomes through cell-based therapies. <b>Conclusions:</b> There is a limited but emerging body of literature on precision medicine in breast reconstruction. Genomic data are the driving force of precision medicine in breast reconstruction, and multiple potential avenues exist to achieve translational applications in the short-term period. Future efforts should focus on translating known genomic data into real-time clinical applications and investing in precision-based research for targeted therapies and regenerative medicine in breast reconstruction.</p>","PeriodicalId":16722,"journal":{"name":"Journal of Personalized Medicine","volume":"15 5","pages":""},"PeriodicalIF":3.0000,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12113009/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Personalized Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jpm15050178","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Personalization of medical care is a significant topic of interest. Precision medicine denotes customized medical treatments based on individual genetic, molecular, and/or biomarker data. We conducted a scoping review to identify studies exploring precision medicine in breast reconstruction. Objectives: (1) To map the existing literature, (2) to identify key concepts, and (3) to discuss current and future clinical implications of precision medicine in breast reconstruction. Eligibility criteria: Indexed journal articles (primary research studies) relating to precision medicine in breast reconstruction written in the English language. Sources of evidence: Medline (via Pubmed), Web of Science, and the Cochrane Library. Charting methods: Data charting of selected studies was performed independently by two reviewers using Microsoft Excel. Any discrepancies in data charting were addressed through inter-reviewer discussion and/or expert review. Results: Of 321 initial records, 9 studies that were published between 2011 and 2025 were included in the final review. Eight studies focused predominantly on genomics, and one study focused predominantly on targeted therapies. Genomic-based studies were frequently implemented to evaluate patient risk and inform clinical decision-making, while targeted therapies were used to optimize reconstructive outcomes through cell-based therapies. Conclusions: There is a limited but emerging body of literature on precision medicine in breast reconstruction. Genomic data are the driving force of precision medicine in breast reconstruction, and multiple potential avenues exist to achieve translational applications in the short-term period. Future efforts should focus on translating known genomic data into real-time clinical applications and investing in precision-based research for targeted therapies and regenerative medicine in breast reconstruction.

2011-2025年乳房再造精准医学研究综述
背景:医疗护理的个性化是一个重要的话题感兴趣。精准医疗是指基于个人基因、分子和/或生物标志物数据的定制医疗。我们进行了一项范围综述,以确定在乳房重建中探索精准医学的研究。目的:(1)梳理现有文献,(2)识别关键概念,(3)探讨精准医学在乳房再造中的当前和未来临床意义。入选标准:以英文撰写的与乳房重建精准医学相关的索引期刊文章(初级研究)。证据来源:Medline(通过Pubmed)、Web of Science和Cochrane Library。作图方法:所选研究的数据由两位审稿人使用Microsoft Excel独立作图。数据图表中的任何差异都通过审稿人之间的讨论和/或专家评审来解决。结果:在321项初始记录中,2011年至2025年间发表的9项研究被纳入最终综述。8项研究主要关注基因组学,1项研究主要关注靶向治疗。基于基因组的研究经常用于评估患者风险并为临床决策提供信息,而靶向治疗则通过基于细胞的治疗来优化重建结果。结论:关于乳房再造的精准医学文献有限,但正在兴起。基因组数据是乳房重建精准医学的推动力,短期内存在多种潜在途径实现转化应用。未来的努力应该集中在将已知的基因组数据转化为实时临床应用,并投资于基于精确的靶向治疗和乳房重建再生医学研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Personalized Medicine
Journal of Personalized Medicine Medicine-Medicine (miscellaneous)
CiteScore
4.10
自引率
0.00%
发文量
1878
审稿时长
11 weeks
期刊介绍: Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., pharmacogenomics/proteomics, systems biology). JPM recognizes that personalized medicine—the assessment of genetic, environmental and host factors that cause variability of individuals—is a challenging, transdisciplinary topic that requires discussions from a range of experts. For a comprehensive perspective of personalized medicine, JPM aims to integrate expertise from the molecular and translational sciences, therapeutics and diagnostics, as well as discussions of regulatory, social, ethical and policy aspects. We provide a forum to bring together academic and clinical researchers, biotechnology, diagnostic and pharmaceutical companies, health professionals, regulatory and ethical experts, and government and regulatory authorities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信